<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83760">
  <stage>Registered</stage>
  <submitdate>27/03/2009</submitdate>
  <approvaldate>18/05/2009</approvaldate>
  <actrnumber>ACTRN12609000296235</actrnumber>
  <trial_identification>
    <studytitle>A phase II trial of PAD (Bortezomib, Doxorubicin and Dexamethasone) induction therapy in transplant-eligible patients with untreated multiple myeloma (MM), stratified for markers of bortezomib resistance.</studytitle>
    <scientifictitle>A phase II trial of PAD (Bortezomib, Doxorubicin and Dexamethasone)  induction therapy in transplant-eligible patients with untreated multiple myeloma (MM), stratified for markers of bortezomib resistance, comparing overall response rate to PAD (Bortezomib, Doxorubicin and Dexamethasone).</scientifictitle>
    <utrn />
    <trialacronym>The PIMMS Trial: The PAD Induction in Multiple Myeloma Stratified Trial</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Multiple Myeloma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Myeloma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Four 21-day cycles of PAD: a combination of bortezomib i.v. (intravenous) 1.3mg/m2 (Days 1,4, 8 and 11), doxorubicin i.v. 20mg/m2 (days 1 and 4) and dexamethasone p.o. (by mouth) (days 1, 2, 4, 5, 8, 9, 11 and 12). 
Days 13 to 21 will be 'rest' days - i.e. no treatment will be given on these days.</interventions>
    <comparator>N/A - Open label study</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To compare the overall response rate following 4 cycles of PAD induction therapy between patients with and without amplification of 1q21 (measured by FISH - Fluorescence In Situ Hybridization ) in their marrow at baseline. Overall response will be measured by a number of factors including M-protein changes, clinical examination, radiological images, bone marrow results and IMWG (International Myeloma Working Group) Uniform Disease Response Criteria.</outcome>
      <timepoint>Disease response assessed monthly for 1 year after first treatment.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To compare the overall response rate to PAD induction therapy 3-months following ASCT (Autologous Stem Cell Transplantation), between patients with and without amplification of 1q21</outcome>
      <timepoint>3-months following ASCT.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the event-free survival and overall survival rate at 2 years after Day 1 Cycle 1 of PAD.</outcome>
      <timepoint>2 years after Day 1 Cycle 1 of PAD</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the effect on overall response rate and overall survival of protein expression of p53, p16, Cyclin D1, bcl2, FGFR3 (Fibroblast growth factor receptor 3) (measured by immunohistochemistry)</outcome>
      <timepoint>At PAD completion and 3-months following ASCT.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess quality of life of patients treated with PAD</outcome>
      <timepoint>At each study visit. There are a total of 15 study visits, performed at: Screening, Day 1 of each Cycle, PBSC (Peripheral Blood Stem Cell) Collection and ASCT visits; then at monthly intervals to 1 year after first treatment; and finally at 2 years after first treatment.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Previously diagnosed with multiple myeloma; eligible for autologous stem cell transplantation; meets pre-treatment lab criteria (as defined within protocol).</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Previously received treatment for multiple myeloma (including prior therapy with radiation or pulsed dexamethasone), except localised radiation to a solitary lesion or plasmacytomas or 4 days of corticosteroid therapy; have a current diagnosis of smoldering multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), or Waldenstrom Macroglobulinemia; have a history of any other malignancy within 5 years before enrolment; have other significant comorbidities</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>23/01/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>105</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Janssen-Cilag Pty Ltd</primarysponsorname>
    <primarysponsoraddress>1 - 5 Khartoum Road
North Ryde
NSW 2113</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Janssen-Cilag Pty Ltd</fundingname>
      <fundingaddress>1 - 5 Khartoum Road
North Ryde
NSW 2113</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine efficacy of treatment with bortezomib (in combination with doxorubicin and dexamethasone) in previously untreated patients with Multiple Myeloma</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Research Ethics Committee</ethicname>
      <ethicaddress>Level 3, Hanson Institute, North Terrace, Adelaide, SA 5000</ethicaddress>
      <ethicapprovaldate>7/11/2008</ethicapprovaldate>
      <hrec>081021</hrec>
      <ethicsubmitdate>17/09/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>Hospital Avenue, Nedlands, WA 6009</ethicaddress>
      <ethicapprovaldate>4/02/2009</ethicapprovaldate>
      <hrec>2008-110</hrec>
      <ethicsubmitdate>1/12/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Ethics Review Committee (Royal Prince Alfred Hospital Zone) - Central Site for NSW</ethicname>
      <ethicaddress>Research Development Building
Level 3, Building 92, Royal Pronce Alfred Hospital, Camperdown, NSW 2050</ethicaddress>
      <ethicapprovaldate>2/10/2008</ethicapprovaldate>
      <hrec>08/RPAH/403</hrec>
      <ethicsubmitdate>9/09/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Bellberry Human Research Ethics Committee</ethicname>
      <ethicaddress>First Floor 71 Anzac Highway, Ashford South, SA 5035</ethicaddress>
      <ethicapprovaldate>8/01/2009</ethicapprovaldate>
      <hrec>A171/08</hrec>
      <ethicsubmitdate>9/12/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Greenslopes Private Hospital Ethics Committee</ethicname>
      <ethicaddress>Newdegate Street, Greenslopes, QLD 4120</ethicaddress>
      <ethicapprovaldate>10/12/2008</ethicapprovaldate>
      <hrec>08/32</hrec>
      <ethicsubmitdate>31/10/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Cabrini Human Research Ethics Committee</ethicname>
      <ethicaddress>183 Wattletree Road, Malvern, VIC 3144</ethicaddress>
      <ethicapprovaldate>10/12/2008</ethicapprovaldate>
      <hrec>05-29-09-08</hrec>
      <ethicsubmitdate>11/09/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Barwon Health Human Research Ethics Committee</ethicname>
      <ethicaddress>The Geelong Hospital, Ryrie Street, P.O. Box 281, Geelong, VIC 3220</ethicaddress>
      <ethicapprovaldate>21/01/2009</ethicapprovaldate>
      <hrec>08/92</hrec>
      <ethicsubmitdate>10/12/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ellie Ashurst</name>
      <address>Janssen-Cilag Pty Ltd
1 - 5 Khartoum Road
North Ryde
NSW 2113</address>
      <phone>+61 2 9815 3485</phone>
      <fax />
      <email>eashurst@its.jnj.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ellie Ashurst</name>
      <address>Janssen-Cilag Pty Ltd
1 - 5 Khartoum Road
North Ryde
NSW 2113</address>
      <phone>+61 2 9815 3485</phone>
      <fax />
      <email>eashurst@its.jnj.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ellie Ashurst</name>
      <address>Janssen-Cilag Pty Ltd
1 - 5 Khartoum Road
North Ryde
NSW 2113</address>
      <phone>+61 2 9815 3485</phone>
      <fax />
      <email>eashurst@its.jnj.com</email>
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>